TRICOR Drug Patent Profile

Which patents cover Tricor, and when can generic versions of Tricor launch?

Tricor is a drug marketed by Abbvie and Abbvie Inc and is included in three NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and sixty-four patent family members in twenty-seven countries.

The generic ingredient in TRICOR is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tricor

A generic version of TRICOR was approved as fenofibrate by RHODES PHARMS on May 13^th, 2005.

Summary for TRICOR

International Patents:	164
US Patents:	2
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	129
Clinical Trials:	20
Patent Applications:	3,665
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for TRICOR
Drug Sales Revenues:	Drug sales revenues for TRICOR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRICOR
What excipients (inactive ingredients) are in TRICOR?	TRICOR excipients list
DailyMed Link:	TRICOR at DailyMed

See drug prices for TRICOR

See drug sales revenues for TRICOR

Recent Clinical Trials for TRICOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of General Medical Sciences (NIGMS)	Phase 2/Phase 3
The University of Texas Medical Branch, Galveston	Phase 2/Phase 3
Shriners Hospitals for Children	Phase 2/Phase 3

See all TRICOR clinical trials

Pharmacology for TRICOR

Drug Class

Peroxisome Proliferator Receptor alpha Agonist

Anatomical Therapeutic Chemical (ATC) Classes for TRICOR

C10AB	Fibrates
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

Paragraph IV (Patent) Challenges for TRICOR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRICOR	Tablets	fenofibrate	48 mg	021656	1	2008-07-01
TRICOR	Tablets	fenofibrate	145 mg	021656	1	2007-10-19

US Patents and Regulatory Information for TRICOR

TRICOR is protected by two US patents.

Patents protecting TRICOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	TRICOR	fenofibrate	TABLET;ORAL	021656-001	Nov 5, 2004	AB	RX	Yes	No
Abbvie	TRICOR (MICRONIZED)	fenofibrate	CAPSULE;ORAL	019304-002	Feb 9, 1998		DISCN	Yes	No
Abbvie	TRICOR	fenofibrate	TABLET;ORAL	021656-002	Nov 5, 2004	AB	RX	Yes	Yes			Y
Abbvie	TRICOR (MICRONIZED)	fenofibrate	CAPSULE;ORAL	019304-003	Jun 30, 1999		DISCN	Yes	No

Expired US Patents for TRICOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	TRICOR	fenofibrate	TABLET;ORAL	021656-002	Nov 5, 2004
Abbvie	TRICOR	fenofibrate	TABLET;ORAL	021656-002	Nov 5, 2004
Abbvie	TRICOR	fenofibrate	TABLET;ORAL	021656-001	Nov 5, 2004
Abbvie	TRICOR	fenofibrate	TABLET;ORAL	021656-001	Nov 5, 2004

International Patents for TRICOR

See the table below for patents covering TRICOR around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H08501073
European Patent Office	2266542	Libération regulée de compositions nanoparticulaires (Controlled release nanoparticulate compositions)
European Patent Office	2283864	Composition liquide contenant des nanoparticules stabilisées d'une substance active (Liquid dosage compositions fo stable nanoparticulate active agents)
Cyprus	1111344